The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).